- Last edited on February 1, 2024
Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | Previous revision | ||
teaching:pharmaceutical-industry-influence [on April 30, 2020] |
teaching:pharmaceutical-industry-influence [on June 19, 2020] |
||
---|---|---|---|
Line 50: | Line 50: | ||
===== Regulatory Capture ===== | ===== Regulatory Capture ===== | ||
* [[https://www.ncbi.nlm.nih.gov/pubmed/12433532|Abraham, J. (2002). The pharmaceutical industry as a political player. The Lancet, 360(9344), 1498-1502.]] | * [[https://www.ncbi.nlm.nih.gov/pubmed/12433532|Abraham, J. (2002). The pharmaceutical industry as a political player. The Lancet, 360(9344), 1498-1502.]] | ||
+ | |||
+ | ===== Clinical Practice Guidelines ===== | ||
+ | * [[https://www.cmaj.ca/content/192/23/E617|Elder, K., Turner, K. A., Cosgrove, L., Lexchin, J., Shnier, A., Moore, A., ... & Thombs, B. D. (2020). Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ, 192(23), E617-E625.]] | ||
===== Reform ===== | ===== Reform ===== | ||
- | <callout>“t is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." | + | <callout>“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." |
\\ \\ | \\ \\ | ||
-- //Dr. Marcia Angell, Drug Companies & Doctors: A Story of Corruption//</callout> | -- //Dr. Marcia Angell, Drug Companies & Doctors: A Story of Corruption//</callout> |